Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07453836) titled 'Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia' on March 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.
Condition:
Autoimmune Hemolytic Anemia
Intervention:
Drug: YTS109 cell
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: March 18, 2026
Target Sample Size: 13
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT0745...